Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population

Table 3 Costs and savings at 3 months per patient

		M0 (EUR)	M3 (EUR)	Monthly balance per patient (EUR)	Total balance (EUR per patient for 3 months of treatment)
Direct Costs	anti-CGRP MAbs	0.0	453.67	-453.67	-1361.0
Direct Costs	Follow-up (1 outpatient visit)^a	0.0	80	-26.7	-80
Direct Savings	Emergency visits	55.6	24.5	+ 31.1	+ 93.3
Direct Savings	Triptans	5.4	2.6	+ 2.8	+ 8.4
Indirect Savings	Absenteeism	330.5	225.1	+ 105.4	+ 316.2
Indirect Savings	Presenteeism	929.7	535.4	+ 394.3	+ 1182.9
				Total per patient	+ 159.8
				TOTAL	+ 23,650.4

^aPatients treated with MAbs received an additional outpatient visit every 3 months during the follow-up, which was encountered in the cost–benefit analysis. The rest of clinical visits were the same as patients with migraine and without this treatment

ISSN: 1129-2377